| HOME >> BIOLOGY >> TECHNOLOGY |
SCOTTSDALE, Ariz., Feb. 19 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Lung Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in non-small cell and small cell lung cancer.
Lung cancer continues to be the leading worldwide cause of cancer death. Researchers are pursuing a broad array of mechanistic approaches to treatment, including angiogenics/VEGF, EGFR resistance (T790M, MET), HER2 (ErbB2), antifolate, anti-microtubule, apoptosis, Bcl-2/Bcl-xL, TRAIL, vascular disrupting agents, Ras, Raf, MEK, mTOR, PI3, AKT, IGF-1, HSP90, HDAC, JAK/STAT, MAGE-A3, CDK, Aurora Kinase, and anticoagulation.
MedPredict conducted primary, qualitative interviews with renowned US-based Thought Leaders in the areas of non-small cell and small cell lung cancer in order to identify the most promising candidates in clinical development, as well as explore unmet needs. "This report will provide essential strategic insight for those involved in development of lung cancer therapies," according to MedPredict President Dr. Jeffrey Berk. "Our Thought Leader Panel discusses ongoing clinical programs, and offers their opinions on which of the myriad new drugs in development are likely to be significant improvements over current options."
Some of the companies/partnerships discussed in this report include: Genentech/Roche, Pfizer, AstraZeneca, GlaxoSmithKline, Onyx/Bayer-Schering, Regeneron/Sanofi-Aventis, Genentech/OSI, Imclone/BMS/Merck Serono, Lilly, Exelixis, Wyeth, Boehringer-Ingelheim, Novartis, Mitsubishi/Aveo, Cell Therapeutics, Abbott/Genentech, Genentech/Amgen, Antisoma/Novartis, Antigenics, Concordia, Prolexys, Critical Outcome Technologies, Merck, Schering-Plough, Infinity/Medimmune/AstraZeneca, Synta, Serenex, Bristol Myers Squibb, Abbott, Millennium, Vertex/Merck, Cyclacel.
The fu
'/>"/>
| SOURCE MedPredict Copyright©2008 PR Newswire. All rights reserved |